CDK4 and endometrioid stromal sarcoma: In line with these findings, MEK inhibitors (e.g., PD325901) and CDK4/6 inhibitors (e.g., palbociclib) demonstrated antiproliferative effects in HG-ESS, with combined therapies showing synergistic activity [52,53].